These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 2476625

  • 1. Beta-adrenoceptor blocking activity of diprafenone in anesthetized dogs: comparison with propafenone and propranolol.
    Greenberg S, Cantor E, Paul J.
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):444-53. PubMed ID: 2476625
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man.
    Wagner F, Jähnchen E, Trenk D.
    Eur J Clin Pharmacol; 1989 Sep; 36(6):579-82. PubMed ID: 2570700
    [Abstract] [Full Text] [Related]

  • 3. Characterization of the beta-adrenoceptor blocking property of diprafenone in rats: stereoselective interaction, subtype specificity, and sensitization.
    Nanoff C, Schütz W.
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):837-42. PubMed ID: 1725895
    [Abstract] [Full Text] [Related]

  • 4. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K, Lindner W, Schnedl H, Kukovetz WR.
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [Abstract] [Full Text] [Related]

  • 5. [Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone].
    Gülker H, Heuer H, Thale J, Behrenbeck T.
    Z Kardiol; 1987 Jul; 76(7):411-4. PubMed ID: 3673162
    [Abstract] [Full Text] [Related]

  • 6. Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies.
    McLeod AA, Stiles GL, Shand DG.
    J Pharmacol Exp Ther; 1984 Feb; 228(2):461-6. PubMed ID: 6141285
    [Abstract] [Full Text] [Related]

  • 7. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action.
    Faber TS, Camm AJ.
    Eur J Clin Pharmacol; 1996 Feb; 51(3-4):199-208. PubMed ID: 9010685
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the apparent irreversible beta-adrenoceptor antagonist Ro 03-7894 with propranolol in cardiac ventricular muscle by pharmacological and radioligand binding techniques.
    Rankin A, Broadley KJ.
    Biochem Pharmacol; 1982 Apr 01; 31(7):1325-32. PubMed ID: 6124256
    [Abstract] [Full Text] [Related]

  • 9. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
    Gülker H, Thale J, Olbing B, Heuer H, Frenking B, Bender F.
    Arzneimittelforschung; 1985 Apr 01; 35(9):1387-93. PubMed ID: 4084340
    [Abstract] [Full Text] [Related]

  • 10. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
    Geibel A, Zehender M, Hohnloser S, Landsrath C, Meinertz T, Just H.
    Z Kardiol; 1988 Jul 01; 77(7):464-9. PubMed ID: 2463720
    [Abstract] [Full Text] [Related]

  • 11. Block of single cardiac Na+ channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone.
    Kohlhardt M, Fichtner H.
    J Membr Biol; 1988 May 01; 102(2):105-19. PubMed ID: 2458471
    [Abstract] [Full Text] [Related]

  • 12. Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties.
    Argentieri TM, Troy HH, Carroll MS, Doroshuk CM, Sullivan ME.
    J Cardiovasc Pharmacol; 1993 Apr 01; 21(4):647-55. PubMed ID: 7681912
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of diprafenone stereoenantiomers on cardiac Na+ channels.
    Kohlhardt M, Fichtner H.
    Eur J Pharmacol; 1988 Oct 26; 156(1):55-62. PubMed ID: 2850211
    [Abstract] [Full Text] [Related]

  • 14. Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers.
    Hinderling PH, Tendolkar A, Dee CM, Barr WH, Seiberling M, Duerr H.
    J Clin Pharmacol; 1995 Jul 26; 35(7):721-9. PubMed ID: 7560253
    [Abstract] [Full Text] [Related]

  • 15. Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).
    Thormann J, Kramer W, Kremer P, Schlepper M.
    Cardiovasc Drugs Ther; 1989 Apr 26; 3(2):145-54. PubMed ID: 2487530
    [Abstract] [Full Text] [Related]

  • 16. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL, Liou SF, Liang JC, Huang YC, Chiang LC, Wu JR, Lin YT, Chen IJ.
    J Cardiovasc Pharmacol; 2000 Jan 26; 35(1):51-63. PubMed ID: 10630733
    [Abstract] [Full Text] [Related]

  • 17. Beta-adrenergic stimulation modulates the sodium current block by propafenone in rat ventricular myocardium.
    Maier SK, Kirstein M.
    J Electrocardiol; 2002 Oct 26; 35(4):343-9. PubMed ID: 12395362
    [Abstract] [Full Text] [Related]

  • 18. Electrophysiological effects of diprafenone, a dimethyl congener of propafenone on guinea-pig ventricular cells.
    Kodama I, Suzuki R, Honjo H, Toyama J.
    Br J Pharmacol; 1992 Nov 26; 107(3):813-20. PubMed ID: 1335340
    [Abstract] [Full Text] [Related]

  • 19. Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist.
    Lin YT, Wu BN, Wu JR, Lo YC, Chen LC, Chen IJ.
    J Cardiovasc Pharmacol; 1996 Jul 26; 28(1):149-57. PubMed ID: 8797149
    [Abstract] [Full Text] [Related]

  • 20. On the mechanism of drug-induced blockade of Na+ currents: interaction of antiarrhythmic compounds with DPI-modified single cardiac Na+ channels.
    Kohlhardt M, Fichtner H, Fröbe U, Herzig JW.
    Circ Res; 1989 May 26; 64(5):867-81. PubMed ID: 2539922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.